[Featured Stock] Celltrion Rises on Demonstrated Efficacy in COVID-19 Treatment Phase 3 Trial

[Asia Economy Reporter Ji Yeon-jin] On the 14th, Celltrion showed strong performance in the early trading session following the news of proving the efficacy of its COVID-19 treatment in Phase 3 clinical trials.

As of 10:05 AM on the same day, Celltrion was trading at 276,000 KRW on the KOSPI market, up 10,000 KRW (3.77%) compared to the previous day. At the same time, Celltrion Healthcare was trading at 121,600 KRW on the KOSDAQ market, up 3.40% from the previous trading day, and Celltrion Pharm recorded a 4.54% increase, reaching 145,100 KRW.

On this day, Celltrion announced that its COVID-19 treatment, Rekkeona, showed clear differences between the treatment group and the placebo group in all primary endpoints analyzed in the Phase 3 clinical trial. Celltrion plans to submit the topline results of this Phase 3 trial to global regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, it plans to announce the global Phase 3 clinical trial results of Rekkeona within the first half of the year.